dc.creator | Kirgou P., Sinis S.I., Dimeas I.E., Papanikolaou I.C., Tatsis K., Gogali A., Gourgoulianis K.I., Bogdanos D.P., Daniil Z. | en |
dc.date.accessioned | 2023-01-31T08:43:19Z | |
dc.date.available | 2023-01-31T08:43:19Z | |
dc.date.issued | 2022 | |
dc.identifier | 10.3389/fmed.2022.964722 | |
dc.identifier.issn | 2296858X | |
dc.identifier.uri | http://hdl.handle.net/11615/74890 | |
dc.description.abstract | Patients with idiopathic pulmonary fibrosis are screened for circulating autoantibodies as part of the initial interstitial lung disease workup. Management of seropositive idiopathic pulmonary fibrosis is currently considered no different than that of lone idiopathic pulmonary fibrosis. Emerging data however suggest that the former may possess distinct characteristics in terms of pathophysiology, histopathology, prognosis and amenability to immunomodulation. In that context, the aim of our study was to evaluate the influence of autoantibody status on: (i) the decline of forced vital capacity; (ii) the decline of diffusing capacity of lung for carbon monoxide; and (iii) 3-year survival; in a cohort of 102 idiopathic pulmonary fibrosis patients. In a pilot sub-study, we also sought to evaluate whether changes in antibody status during disease course affect the aforementioned parameters by potentially reflecting activity of the autoimmunity component of the pro-fibrotic mechanism. Copyright © 2022 Kirgou, Sinis, Dimeas, Papanikolaou, Tatsis, Gogali, Gourgoulianis, Bogdanos and Daniil. | en |
dc.language.iso | en | en |
dc.source | Frontiers in Medicine | en |
dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85136467806&doi=10.3389%2ffmed.2022.964722&partnerID=40&md5=71600ead65b8957ae1ac8ba8393a2906 | |
dc.subject | autoantibody | en |
dc.subject | adult | en |
dc.subject | aged | en |
dc.subject | antibody detection | en |
dc.subject | Article | en |
dc.subject | autoimmunity | en |
dc.subject | carbon monoxide blood level | en |
dc.subject | cohort analysis | en |
dc.subject | controlled study | en |
dc.subject | disease course | en |
dc.subject | female | en |
dc.subject | fibrosing alveolitis | en |
dc.subject | follow up | en |
dc.subject | Greece | en |
dc.subject | human | en |
dc.subject | innate immunity | en |
dc.subject | interstitial lung disease | en |
dc.subject | lung diffusion capacity | en |
dc.subject | lung function test | en |
dc.subject | major clinical study | en |
dc.subject | male | en |
dc.subject | pilot study | en |
dc.subject | respiratory tract parameters | en |
dc.subject | serodiagnosis | en |
dc.subject | survival | en |
dc.subject | Frontiers Media S.A. | en |
dc.title | Clinical relevance of circulating autoantibodies in idiopathic pulmonary fibrosis; A NAt hard to break | en |
dc.type | journalArticle | en |